NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free LRMR Stock Alerts $9.59 +0.09 (+0.95%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$9.40▼$10.0050-Day Range$6.33▼$9.8952-Week Range$2.18▼$13.68Volume344,900 shsAverage Volume549,569 shsMarket Capitalization$611.86 millionP/E RatioN/ADividend YieldN/APrice Target$21.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Larimar Therapeutics alerts: Email Address Larimar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside122.5% Upside$21.33 Price TargetShort InterestBearish6.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.29) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector737th out of 903 stocksPharmaceutical Preparations Industry349th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.13% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 0.26%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LRMR. Previous Next 2.6 News and Social Media Coverage News SentimentLarimar Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Larimar Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for LRMR on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.29) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -9.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -9.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 5.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Larimar Therapeutics Stock (NASDAQ:LRMR)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Read More LRMR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LRMR Stock News HeadlinesJune 1, 2024 | americanbankingnews.comLarimar Therapeutics' (LRMR) Market Outperform Rating Reaffirmed at JMP SecuritiesMay 31, 2024 | seekingalpha.comLarimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely RemovedMay 30, 2024 | globenewswire.comLarimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's AtaxiaMay 29, 2024 | fool.com2 Potentially High-Reward Growth Stocks to Buy Right NowMay 22, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Larimar Therapeutics Post FDA Clinical Hold Lift and Positive Drug Trial TrajectoryMay 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics as FDA Lifts Hold on Promising Drug NomlabofuspMay 21, 2024 | msn.comLarimar Therapeutics Advances Friedreich's Ataxia Treatment After FDA Lifts HoldMay 21, 2024 | msn.comLarimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed DrugMay 21, 2024 | markets.businessinsider.comLarimar Therapeutics Says FDA Lifted Partial Clinical Hold For Nomlabofusp In Friedreich's AtaxiaMay 20, 2024 | markets.businessinsider.comOptimistic Outlook for Larimar Therapeutics’ Nomlabofusp Following FDA’s Lifted Partial HoldMay 20, 2024 | finance.yahoo.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s AtaxiaMay 20, 2024 | globenewswire.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's AtaxiaMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Larimar Therapeutics Backed by Positive Phase 2 Results and Strategic FDA DiscussionsMay 10, 2024 | finance.yahoo.comCompanies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating for Larimar Therapeutics Backed by Strong Clinical and Financial OutlookMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics Amid Promising Phase II Data and Strategic OLE Study for FA TreatmentMay 9, 2024 | msn.comLarimar Therapeutics files for $300M mixed shelf offeringMay 9, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024May 9, 2024 | washingtonpost.comLarimar: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comLarimar Therapeutics Reports First Quarter 2024 Operating and Financial ResultsMarch 18, 2024 | msn.com5 Stocks that Analysts Love in March 2024March 16, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 callMarch 16, 2024 | markets.businessinsider.comBuy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug NomlabofuspMarch 14, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023March 14, 2024 | sfgate.comLarimar: Q4 Earnings SnapshotSee More Headlines Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/09/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LRMR CUSIPN/A CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$21.33 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+122.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.69% Return on Assets-32.21% Debt Debt-to-Equity RatioN/A Current Ratio17.99 Quick Ratio17.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book5.16Miscellaneous Outstanding Shares63,802,000Free Float61,059,000Market Cap$611.86 million OptionableOptionable Beta0.88 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 65)CEO, President & Director Comp: $865kMr. Michael Celano CPA (Age 65)Secretary & CFO Comp: $577.58kDr. Gopi Shankar M.B.A. (Age 53)Ph.D., Chief Development Officer Comp: $593.02kMr. John BermanVice President of Finance & AdministrationMs. Jennifer Spokes JohanssonVice President of Legal & ComplianceDr. Russell G. Clayton Sr. (Age 63)D.O, D.O., Chief Medical Officer Mr. Francis Michael Conway CPAVP & ControllerMore ExecutivesKey CompetitorsArbutus BiopharmaNASDAQ:ABUSFulcrum TherapeuticsNASDAQ:FULCAltimmuneNASDAQ:ALTKamadaNASDAQ:KMDAParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Sold 449,087 shares on 5/29/2024Ownership: 0.273%Virtu Financial LLCBought 17,578 shares on 5/20/2024Ownership: 0.028%RA Capital Management L.P.Bought 6,045,351 shares on 5/17/2024Ownership: 9.475%Ikarian Capital LLCSold 164,340 shares on 5/17/2024Ownership: 0.687%Janus Henderson Group PLCBought 1,379,900 shares on 5/16/2024Ownership: 6.302%View All Insider TransactionsView All Institutional Transactions LRMR Stock Analysis - Frequently Asked Questions Should I buy or sell Larimar Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares. View LRMR analyst ratings or view top-rated stocks. What is Larimar Therapeutics' stock price target for 2024? 6 equities research analysts have issued twelve-month price objectives for Larimar Therapeutics' stock. Their LRMR share price targets range from $14.00 to $25.00. On average, they predict the company's share price to reach $21.33 in the next year. This suggests a possible upside of 122.5% from the stock's current price. View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts. How have LRMR shares performed in 2024? Larimar Therapeutics' stock was trading at $4.55 on January 1st, 2024. Since then, LRMR shares have increased by 110.8% and is now trading at $9.59. View the best growth stocks for 2024 here. When is Larimar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our LRMR earnings forecast. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.03. What ETF holds Larimar Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,867 shares of LRMR stock, representing 0.40% of its portfolio. Who are Larimar Therapeutics' major shareholders? Larimar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.48%), Janus Henderson Group PLC (6.30%), Vanguard Group Inc. (3.71%), StemPoint Capital LP (1.16%), Assenagon Asset Management S.A. (1.00%) and Ikarian Capital LLC (0.69%). Insiders that own company stock include Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LRMR) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.